Navigation Links
Depo-Provera Birth Control Might Raise Breast Cancer Risk
Date:4/4/2012

WEDNESDAY, April 4 (HealthDay News) -- There appears to be a link between an injectable form of progestin-only birth control, best known as Depo-Provera, and an increased risk of breast cancer in young women, new research suggests.

For the study, researchers compared more than 1,000 Seattle-area women, aged 20 to 44, who were diagnosed with breast cancer, and more than 900 women without breast cancer.

Recent use of the injectable contraceptive (formally called depo-medroxyprogesterone acetate or DMPA) for a year or longer was associated with a 2.2-fold increased risk of invasive breast cancer, the study found.

This increased risk appeared to fade within months after women stopped using the contraceptive, and women who used the contraceptive for less than a year or who had stopped using it more than a year earlier did not have any increased risk of breast cancer, according to the findings published online and in the April 15 print issue of the journal Cancer Research.

"Although breast cancer is rare among young women and the elevated risk of breast cancer associated with DMPA appears to dissipate after discontinuation of use, our findings emphasize the importance of identifying the potential risks associated with specific forms of contraceptives given the number of available alternatives," study leader Dr. Christopher Li, a breast cancer epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle, and colleagues wrote.

"In the United States, many women have numerous options for contraception, and so it is important to balance their risks and benefits when making contraceptive choices," Li noted in a news release from the research center.

While the study uncovered an association between Depo-Provera and raised breast cancer risk, it could not prove a cause-and-effect relationship.

Commenting on the study, Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, said, "This study further confirms that some types of progestins are not healthy for the breast. For women who are at elevated risk to develop breast cancer based on family history, or even age, this type of contraception may not be a good choice for them."

But another expert cautioned that the study did have its limits.

Dr. Freya Schnabel, director of breast surgery at NYU Clinical Cancer Center in New York City, noted that the women in the study who seemed at highest risk of developing breast cancer while on Depo-Provera were those with a family history of the disease or women who had never had children (another known risk factor).

Furthermore, she said, "the study did not include information about all breast cancer risk factors in the participants, and this is a real limitation of the analysis which could impact on the results. Also, the mechanism by which the progesterone would increase risk only in current users is not clear."

According to Schnabel, all of this means that "more detailed studies are needed to clarify the relationship between this contraceptive method and risk of breast cancer."

The research was funded by the U.S. National Cancer Institute and the Department of Defense Breast Cancer Research Program.

More information

Planned Parenthood has more about the birth control shot.

-- Robert Preidt

SOURCES: Elizabeth Poynor, M.D., Ph.D., Lenox Hill Hospital, New York City; Freya Schnabel, M.D., director of breast surgery, NYU Clinical Cancer Center, New York City; Fred Hutchinson Cancer Research Center, news release, April 4, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Giving Birth to Small Babies Linked to Heart Disease in Moms: Study
2. Late Preemie Birth May Be Linked to Higher Asthma Risk
3. Timing of Preemie Birth May Be Key to Kids Health Later
4. Another Batch of Birth Control Pills Recalled for Faulty Packaging
5. Women with rheumatoid arthritis and lupus give birth to fewer children
6. Weekend Delivery Doesnt Hurt Babies With Birth Defects: Study
7. Study weighs risks and benefits of birthing facilities
8. Risk of Preterm Birth Rises for Hispanic Women the Longer Theyre in U.S.
9. Study finds residence in US a risk factor for preterm birth
10. Pfizer Recalls 1 Million Packets of Birth Control Pills
11. When Mom-to-Bes Overweight and Smokes, Risk for Birth Defects Rises
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Depo-Provera Birth Control Might Raise Breast Cancer Risk
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated this ... Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek ... winner is the Center for American Progress (CAP), for its report, Lessons From State ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology: